This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Australia’s PEP, Carlyle Group team up for iNova Pharmaceuticals bid

( March 31, 2017, 07:02 GMT | Insight) -- Australia's Pacific Equity Partners has teamed up with US private equity major Carlyle Group in a joint bid for iNova Pharmaceuticals that is expected to be worth about A$1 billion ($765.1 million), the Australian Financial Review reports. Australia's Pacific Equity Partners has teamed up with US private equity major Carlyle Group in a joint bid for iNova Pharmaceuticals that is expected to be worth about A$1 billion ($765.1 million), the Australian Financial Review reports. US-based Valeant Pharmaceuticals, which owns iNova, put the company up for auction in late 2016. Pacific Equity Partners and Carlyle could be up against a bid by Mundipharma, a foreign-owned firm with Australian operations. Sydney-based iNova develops and sells over-the-counter and prescription medicines under some well-known brand names such as Difflam and Bausch & Lomb. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login